Mirum Pharmaceuticals — Third Quarter 2026 Earnings Summary

Mirum Pharmaceuticals reported third-quarter 2026 net product sales of $185.7 million, driven by $133.4 million in LIVMARLI sales and $52.3 million in Bile Acid Medicines sales. The company raised its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the U.S. FDA approval and launch of ATEBRIOZ for fibrodysplasia ossificans progressiva. Clinical updates included positive Phase 3 results for LIVMARLI in biliary atresia and brelovitug in chronic hepatitis delta virus, with regulatory submissions planned for the first half of 2027. Total operating expenses for the quarter reached $245.5 million, resulting in a net loss of $40.8 million, while the company maintained unrestricted cash and investments of $500.5 million.